Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
12.97B
Market cap12.97B
Price-Earnings ratio
-31.89
Price-Earnings ratio-31.89
Dividend yield
Dividend yield
Average volume
2.54M
Average volume2.54M
High today
$79.27
High today$79.27
Low today
$77.67
Low today$77.67
Open price
$79.09
Open price$79.09
Volume
1.07M
Volume1.07M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$23.95
52 Week low$23.95

Stock Snapshot

The current Ionis Pharmaceuticals(IONS) stock price is $78.51, with a market capitalization of 12.97B. The stock trades at a price-to-earnings (P/E) ratio of -31.89.

On 2026-03-04, Ionis Pharmaceuticals(IONS) stock traded between a low of $77.67 and a high of $79.27. Shares are currently priced at $78.51, which is +1.1% above the low and -1.0% below the high.

The Ionis Pharmaceuticals(IONS)'s current trading volume is 1.07M, compared to an average daily volume of 2.54M.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $23.95 at its lowest and $86.74 at its peak.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $23.95 at its lowest and $86.74 at its peak.

IONS News

Investing.com 2d
Ionis Pharmaceuticals at TD Cowen Conference: Strategic Growth Insights - Investing.com

...

Ionis Pharmaceuticals at TD Cowen Conference: Strategic Growth Insights - Investing.com
Simply Wall St 4d
Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story

Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline. N...

Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story
TipRanks 5d
Ionis Pharmaceuticals price target raised to $100 from $87 at Piper Sandler

Piper Sandler analyst Allison Bratzel raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $87 and keeps an Overweight rating on the shar...

Analyst ratings

74%

of 23 ratings
Buy
73.9%
Hold
26.1%
Sell
0%

More IONS News

Simply Wall St 5d
A Look At Ionis Pharmaceuticals Valuation After Strong One Year Returns And Large Estimated DCF Upside

Advertisement Ionis Pharmaceuticals overview and recent share performance Ionis Pharmaceuticals (IONS) has drawn investor attention recently, with the share p...

A Look At Ionis Pharmaceuticals Valuation After Strong One Year Returns And Large Estimated DCF Upside
TipRanks 7d
Ionis Pharmaceuticals Earnings Call Highlights Surging Momentum

Ionis Pharmaceuticals Inc. ((IONS)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund...

TipRanks 7d
Ionis Pharmaceuticals: Accelerating Commercial Momentum, Conservative Guidance, and Late-Stage Pipeline Catalysts Underpin Buy Rating

Analyst Yaron Werber of TD Cowen maintained a Buy rating on Ionis Pharmaceuticals, boosting the price target to $110.00. Yaron Werber has given his Buy rating...

TipRanks 7d
Ionis Pharmaceuticals: Strong 4Q25 Beat and Catalyst-Rich 2026 Underpin Raised Buy Rating and $103 Target

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $103.00. Joseph Stringer has...

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.